Therapeutic Switching and Sequencing in Multiple Sclerosis: Implementing Expert Strategies for Improved Clinical and Economic Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2020 to January 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Biogen, Genentech, and Sanofi Genzyme

Multiple sclerosis (MS) is an unpredictable disease of the central nervous system (CNS) that disrupts the flow of information within the brain, and between the brain and the body. It involves an abnormal response of the immune system against the central nervous system, causing damaging inflammation.
In many cases, multiple sclerosis may not be diagnosed for months to years after the onset of symptoms. Some strategies for diagnosis include a careful medical history, a neurologic exam and various tests, including magnetic resonance imaging (MRI), evoked potentials (EP) and spinal fluid analysis. Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage symptoms and improve their quality of life. Recent years have witnessed remarkable progress in our understanding of the complex mechanisms involved in multiple sclerosis (MS). Some new options showing improved efficacy, safety and deliverability have recently completed clinical trials and are currently undergoing regulatory review.

Upon completion of this activity, participants will be able to:

  • Identify key indicators of multiple sclerosis (MS) to improve early diagnosis and initiation of treatment for MS

  • Evaluate the latest data on the efficacy, safety, and dosing/administration of current and emerging therapies and their effect on staging and sequencing

  • Examine recently updated evidence-based data for the rationale of sequencing, switching, and/or escalating MS therapeutics

  • Employ utilization management and benefit design strategies for MS therapies to enhance clinical and economic outcomes for patients with MS

  • Analyze care pathways and their application to manage and improve economic outcomes in MS

  • Apply knowledge about MS therapies and aspects of a patient's presentation to make an informed decision when switching MS therapies

Faculty: Robert Bermel, MD
Director, Mellen Center for Multiple Sclerosis
Cleveland Clinic


Dr. Bermel serves as a consultant for Biogen, Genentech, Genzyme, and Novartis. He has received grant/research support from Biogen, Genentech, and Novartis. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Biogen, Genentech, and Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue